Trial Profile
A Phase I/II Clinical Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Melphalan (Primary) ; Prednisolone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 16 Apr 2012 Actual patient number changed from 81 to 99 as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual end date Jun 2010 added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.